TORONTO, Jan. 8, 2025 /PRNewswire/ — AmacaThera, a leading clinical-stage biotechnology company revolutionizing long-acting therapies, announces the appointment of Dr. Eyal S. Ron to its Board of Directors. A seasoned entrepreneur and life sciences strategist, […]
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric […]
SILVER SPRING, Md., Dec. 13, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric […]
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Dec. 13, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company“) […]
SILVER SPRING, Md., Dec. 13, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA’s Center for Drug Evaluation and […]
